NSCLC 2023 Data Updates: Shaping the Future Treatment Landscape

Opinion
Video

Eduardo Santos, MD, FACP, FCCP, highlights the most impactful and treatment-changing data updates for NSCLC in 2023, and provides perspective on how these finding may shape the future direction of care.

Related Videos
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"
Video 7 - "Comorbidity Considerations for HCC Treatment"
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Video 8 - "Future Outlook for RET Fusion-Targeted Therapies"
Video 7 - "Impact and Positioning of Tumor Agnostic Approvals"
Video 14 - "Toxicity Profiles for DTC Guidelines Therapies"
Related Content
Andrew Joe, MD

FDA Grants Priority Review to Zenocutuzumab BLA for NRG1+ NSCLC and Pancreatic Cancer

May 7th 2024
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
Yuankai Shi, MD, PhD, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Glecirasib Generates Durable Responses in Pretreated Advanced KRAS G12C+ NSCLC

April 30th 2024
Article
Adnan F. Danish, MD

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023
Podcast
Raj Singh, MD, of The Ohio State University Comprehensive Cancer Center––James

Singh Discusses the Shift Toward Stereotactic Radiation Therapy in Lung Cancer

April 23rd 2024
Article
Mark Lanasa, MD, PhD

Tislelizumab Receives EU Approval in 3 Indications for First- and Second-Line NSCLC

April 23rd 2024
Article